Provided by Tiger Fintech (Singapore) Pte. Ltd.

SIGA Technologies Inc.

5.71
+0.24004.39%
Post-market: 5.70-0.0100-0.18%18:06 EST
Volume:404.28K
Turnover:2.26M
Market Cap:407.72M
PE:4.78
High:5.75
Open:5.41
Low:5.36
Close:5.47
Loading ...

Siga Technologies approved in Japan for treatment of orthopoxviruses

TIPRANKS
·
02 Jan

Tepoxx (Tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses

THOMSON REUTERS
·
02 Jan

SIGA Technologies Inc - Japan Biotechno Pharma to Supply Tepoxx to National Stockpile

THOMSON REUTERS
·
02 Jan

Are Investors Undervaluing Siga Technologies (SIGA) Right Now?

Zacks
·
25 Dec 2024

Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket

Benzinga
·
23 Dec 2024

Undiscovered Gems In The United States To Explore December 2024

Simply Wall St.
·
20 Dec 2024

Is Siga Technologies (SIGA) Stock Outpacing Its Medical Peers This Year?

Zacks
·
11 Dec 2024

BRIEF-Interim Results From Stomp Study Of Siga’S Tecovirimat In Treatment Of Mpox Announced

Reuters
·
11 Dec 2024

UPDATE 1-Siga's mpox drug did not improve lesion resolution or pain, NIH study finds

Reuters
·
11 Dec 2024

SIGA Technologies Inc - Study Stopped Enrolling Patients in All Study Arms

THOMSON REUTERS
·
11 Dec 2024

Interim Results From Stomp Study of SIGA’s Tecovirimat in Treatment of Mpox Announced

THOMSON REUTERS
·
11 Dec 2024

Interim Results from STOMP Study of SIGA’s Tecovirimat in Treatment of Mpox Announced

GlobeNewswire
·
11 Dec 2024

Nih: Nih Study Finds Tecovirimat Was Safe but Did Not Improve Mpox Resolution or Pain - Website

THOMSON REUTERS
·
11 Dec 2024

Nih: Data Safety and Monitoring Board Recommended Stopping Further Enrollment of Participants Who Were Being Randomized to Tecovirimat or Placebo

THOMSON REUTERS
·
11 Dec 2024

NIH study finds Siga’s tecovirimat did not improve Mpox resolution or pain

TIPRANKS
·
11 Dec 2024

Should Value Investors Buy Siga Technologies (SIGA) Stock?

Zacks
·
09 Dec 2024